Neurodevelopmental Outcomes in Children of Mothers with Epilepsy Taking Antiepileptic Drugs

No differences in cognitive outcomes were seen at 2 years of age between children of women with epilepsy and those of healthy women.

Previous research on teratogenicity of antiepileptic drugs (AEDs) has been limited in the drugs and doses studied. For example, in the Neurodevelopmental Effects of Antiepileptic Drugs study, which examined carbamazepine, lamotrigine, phenytoin, and valproate, exposure to valproate was associated clearly and dose-dependently with worse cognitive performance of children at age 6 years. The Maternal Outcomes and Neurodevelopmental Effects (MONEAD) study is a second prospective observational study to investigate exposure to AEDs and cognitive and behavioral risk in offspring of pregnant women with epilepsy (PWWE). This first report on MONEAD cognitive outcomes is confined to children at age 2 years and focused on maternal AED blood levels (ABL…

Reviewing Author

Robert C. Knowlton, MD, MSPH

Disclosures

Consultant/Advisory BoardMore Health, Inc.; The Alliance of Medical Companies

Grant/Research SupportNIH Small Business Innovation Research

Leadership Positions in Professional SocietiesSouthern Epilepsy & EEG Society (Treasurer)

Robert C. Knowlton, MD, MSPH

Disclosures

Consultant/Advisory BoardMore Health, Inc.; The Alliance of Medical Companies

Grant/Research SupportNIH Small Business Innovation Research

Leadership Positions in Professional SocietiesSouthern Epilepsy & EEG Society (Treasurer)

Neurodevelopmental Outcomes in Children of Mothers with Epilepsy Taking Antiepileptic Drugs

Topics

Reviewing Author